February 9, 2018
Clock Protein Controls Daily Cycle of Gene Expression by Regulating Chromosome Loops, Finds Penn StudyNew understanding of Rev-erb’s role has implications for metabolic disorders, cardiovascular disease, and cancer
It’s well known that the human body functions on a 24-hour, or circadian, schedule. The up-and-down daily cycles of a long-studied clock protein called Rev-erb coordinates the ebb and flow of gene expression by tightening and loosening loops in chromosomes, according to new research from thePerelman School of Medicine at the University of Pennsylvania. The findings appear online this week in Science First Release.
Over the last 15-plus years, a team led by the new study’s senior author Mitchell A. Lazar, MD, PhD, director of Penn’s Institute for Diabetes, Obesity, and Metabolism, has been teasing out the versatile role of Rev-erb in maintaining daily cycles of the body’s molecular clock, metabolism, and even brain health.
November 28, 2017
Real-time CGM Improves Hypoglycemic Awareness
Adults with long-standing type 1 diabetes may increase awareness of hypoglycemia and reduce severity of hypoglycemic events by using real-time continuous glucose monitoring, but the endogenous glucose counterregulation is only modestly improved, study data show.
“In long-standing type 1 diabetes, patients can develop reduced symptom awareness of hypoglycemia that can contribute to experiencing severe hypoglycemia episodes where assistance from another person is required and can result in seizures and coma,” Michael R. Rickels, MD, MS, associate professor of medicine in the division of endocrinology, diabetes and metabolism at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, told Endocrine Today. “This study was undertaken to determine if real-time knowledge of glucose levels, available continuously from a CGM, can specifically help the patients who are having the most problematic hypoglycemia to experience less low blood glucose and recover symptom awareness and physiologic defenses against the development of low blood glucose.”